TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12865039
Drug: Nondihydropyridine CCB
Normalized name: 4-(2'-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsäuredimethylester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nondihydropyridine CCB (verapamil SR 240 mg/day)
Study: 12865039
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor (trandolapril 2 mg/day)
Study: 12865039
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of verapamil SR (180 mg/day) plus trandolapril (2 mg/day)
Study: 12865039
Drug: Verapamil SR
Normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil SR (180 mg/day) plus trandolapril (2 mg/day)
Study: 7487856
Drug: Specific manual‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific manual‐based treatment at the clinic
Study: 7487856
Drug: Specific manual‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific manual‐based treatment in the home
Study: 7487856
Drug: General manual‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: General manual‐based treatment in the home
Study: 7487856
Drug: General manual‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: General manual‐based treatment at the clinic
Study: 6996620
Drug: FPL 52758
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPL 52758 (10 microgram, i.d. injection)
Study: 6996620
Drug: FPL 52758
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPL 52758 (1.5 mg, topical application under occlusion for 24 hours)
Study: 6996620
Drug: FPL 57787
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPL 57787 (5% ointment)
Study: 27894306
Drug: Killed whole-HIV
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Killed whole-HIV vaccine, SAV001
Study: 27894306
Drug: Killed whole-HIV
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Killed whole-HIV vaccine, SAV001 with adjuvant
Study: 19875684
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg sildenafil
Study: 16418408
Drug: 7-day triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day triple therapy (20 mg of rabeprazole, 500 mg of clarithromycin, and 1 g of amoxicillin)
Study: 16418408
Drug: 10-day sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day sequential regimen (20 mg of rabeprazole plus 1 g of amoxicillin for 5 days and 20 mg of rabeprazole, 500 mg of clarithromycin, and 500 mg of tinidazole for the remaining 5 days)
Study: 24158898
Drug: 10-day sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day sequential regimen
Study: 10594394
Drug: Methotrexate 15
Normalized name: methotrexate 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 15 mg/week
Study: 10594394
Drug: Methotrexate 25
Normalized name: methotrexate 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 25 mg/week
Study: 10594394
Drug: Methotrexate dose
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate dose escalation from 15 to 25 mg/week
Study: 8686833
Drug: pethidine 25
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pethidine 25 mg (1 ml)
Study: 8686833
Drug: lignocaine 10
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: lignocaine 10 mg (1 ml)
Study: 9613278
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline (1 ml)
Study: 1776542
Drug: Behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior therapy plus cognitive therapy (BT + CT)
Study: 1776542
Drug: Behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior therapy plus nutrition education (BT + NE)
Study: 1776542
Drug: Behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior therapy plus cognitive therapy and nutrition education (BT + CT + NE)
Study: 1776542
Drug: Behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior therapy plus social support (BT)
Study: 7315774
Drug: Beef diet
Normalized name: Beef
DrugBank: Beef (DB10509)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beef diet (one egg and at least 5 oz of beef daily for 3 months)
Study: 7315774
Drug: Poultry and
Normalized name: Cocci-Cure P for Poultry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poultry and fish diet (one egg and at least 5 oz of poultry and fish daily for 3 months)
Study: 3882217
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (doxorubicin ≤ 550 mg/m2, cyclophosphamide ≤ 5500 mg/m2, methotrexate ≤ 1000 mg/kg)
Study: 27897610
Drug: Calcitriol (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol (1,000 IU daily for 6 weeks)
Study: 23989533
Drug: Tecadenoson (75,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tecadenoson (75, 150, or 300 μg intravenous)
Study: 23989533
Drug: Esmolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (100 μg/kg/min for 10 min then 50 μg/kg/min for 50 min)
Study: 23989533
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Tecadenoson and Esmolol
Study: 23025048
Drug: Emoxipin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emoxipin (single dose, 150 mg)
Study: 23025048
Drug: Mexidol (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexidol (single dose, 300 mg)
Study: 23025048
Drug: Reamberin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reamberin (single dose, 400 ml 1.5% solution)
Study: 11802037
Drug: Intranasal azelastine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal azelastine (two puffs twice a day, 548 microg/d for 2 weeks)
Study: 8631089
Drug: 20 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 micrograms recombinant DNA vaccinia vaccines against hepatitis B; administered at newborn, 1 month, and 6 months.
Study: 8631089
Drug: 20 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 micrograms genetic engineering vaccines against hepatitis B; administered at same intervals as group 1.
Study: 8631089
Drug: 10 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micrograms genetic engineering vaccines against hepatitis B plus HBIG (1ml, 200 U/ml); administered at same intervals as group 1.
Study: 2178852
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (behavioral smoking-cessation program without nicotine patch)
Study: 29661838
Drug: MitoQ (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: MitoQ (20 mg/d)
Study: 24521874
Drug: Topiramate (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (100 mg/day over four weeks)
Study: 8382534
Drug: Nefazodone 50
Normalized name: NEFAZODONE 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone 50 mg
Study: 8382534
Drug: Nefazodone 100
Normalized name: NEFAZODONE 100MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone 100 mg
Study: 8382534
Drug: Nefazodone 200
Normalized name: NEFAZODONE 200MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone 200 mg
Study: 8382534
Drug: Nefazodone (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone (all doses)
Study: 23980081
Drug: Ibandronate 50
Normalized name: ibandronic acid 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate 50 mg per day orally for 2 years
Study: 16430377
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CsA) 0.625 mg/kg/dose
Study: 16430377
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CsA) 1.25 mg/kg/dose
Study: 16430377
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CsA) 2.5 mg/kg/dose
Study: 12971850
Drug: rt‐PA at
Approvals — FDA: no, EMA: no, PMDA: no
Description: rt‐PA at 0.9 mg/kg
Study: 12971850
Drug: rt‐PA at
Approvals — FDA: no, EMA: no, PMDA: no
Description: rt‐PA at 0.7 mg/kg
Study: 12971850
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no thrombolytic therapy)
Study: 10671904
Drug: sibutramine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: sibutramine 20 mg + 0.5 g kg‐1 alcohol
Study: 10671904
Drug: sibutramine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: sibutramine 20 mg + placebo alcohol
Study: 10671904
Drug: placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsules + 0.5 g kg‐1 alcohol
Study: 10671904
Drug: placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsules + placebo alcohol
Study: 9347598
Drug: Gabapentin (2400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (2400 mg over 48 h)
Study: 8407006
Drug: Intracoronary nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary nifedipine (0.2 mg)
Study: 3536231
Drug: Oral prednisolone/prednisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone/prednisone for four months
Study: 3536231
Drug: No corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No corticosteroid therapy (Control)
Study: 30953107
Drug: Evolocumab 420
Normalized name: evolocumab 420 in 3.5 ML Cartridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab 420 mg s.c.
Study: 29733447
Drug: Colchicine 0.6
Normalized name: colchicine 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 0.6 mg
Study: 25288048
Drug: Sham therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham therapy (neck massage)
Study: 16735449
Drug: Rosiglitazone with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone with lipid infusion
Study: 12749425
Drug: Modified long
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified long protocol (standard agonist dose until pituitary down-regulation, then halved during stimulation)
Study: 12749425
Drug: Modified flare
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified flare protocol (high dose of GnRH agonist for first 4 days, then standard agonist dose)
Study: 8140941
Drug: Cyclic estrogen‐progestagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic estrogen‐progestagen replacement treatment plus nandrolone decanoate (ND)
Study: 8140941
Drug: Cyclic estrogen‐progestagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic estrogen‐progestagen replacement treatment (control group)
Study: 21418411
Drug: Control (without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (without irrigant solution)
Study: 17620776
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (HA) injection at 4 weeks after surgery
Study: 17620776
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (HA) injection at 8 weeks after surgery
Study: 17620776
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (HA) injection at 12 weeks after surgery
Study: 17620776
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline injection at 4 weeks after surgery (Control)
Study: 14982985
Drug: Furosemide 20
Normalized name: furosemide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 20 mg (2 mL)
Study: 11167437
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg intrathecal diamorphine
Study: 11167437
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg intrathecal diamorphine
Study: 7796796
Drug: Felbamate, titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felbamate, titrated to a maximum daily dose of 3600 mg over 2 days
Study: 520397
Drug: Propranolol 7.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 7.5, 15 and 30 mg i.v.
Study: 520397
Drug: Labetalol 30,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol 30, 60 and 120 mg i.v.
Study: 520397
Drug: Both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drugs (Propranolol and Labetalol)
Study: 30694752
Drug: Epinephrine in
Normalized name: epinephrine Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine in one‐per‐mil tumescent solution (1:1,000,000 epinephrine and 0.2% lidocaine)
Study: 28143679
Drug: Exercise intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exercise intervention (12 weeks, twice per week)
Study: 25875131
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of buried interrupted subcuticular sutures and adhesive strips
Study: 17121193
Drug: Psychological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological treatment before dental procedures
Study: 17121193
Drug: No psychological
Approvals — FDA: no, EMA: no, PMDA: no
Description: No psychological treatment before dental procedures
Study: 28624819
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline (control group)
Study: 9223200
Drug: Intravenous ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketorolac 15 mg every 6 hours
Study: 9223200
Drug: Intravenous ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketorolac 30 mg every 6 hours
Study: 9223200
Drug: Ketorolac added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac added to PCA morphine on a milligram per milligram basis
Study: 7936530
Drug: Intraperitoneal lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal lidocaine (80 mL of 0.5% lidocaine with 1/320,000 epinephrine and 10 mL of 2% lidocaine with 1/80,000 epinephrine)
Study: 30009652
Drug: Intradermal acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal acupuncture (IA)
Study: 30009652
Drug: Sham intradermal
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham intradermal acupuncture (sham IA)
Study: 27184542
Drug: Pure Platelet-Rich
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pure Platelet-Rich Plasma (PRP) injection
Study: 27184542
Drug: Ropivacaine injection
Normalized name: ROPivacaine Injection
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ropivacaine injection (control)
Study: 25512256
Drug: Supersaturated oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supersaturated oxygen (SSO2) infusion via left main coronary artery (LMCA) for 60 minutes after primary percutaneous coronary intervention (PCI)
Study: 22898575
Drug: Balance exercise
Normalized name: Rebalance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balance exercise therapy (14 training sessions of stretching, strengthening, and balance training)
Study: 17890244
Drug: Everolimus and
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus and low-dose cyclosporine with early steroid avoidance (group A)
Study: 17890244
Drug: Low-dose steroid
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose steroid treatment (group B)
Study: 15938589
Drug: Glimepiride plus
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glimepiride plus metformin (2 mg/day + 1500 mg/day)
Study: 15938589
Drug: Rosiglitazone plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone plus metformin (4 mg/day + 1500 mg/day)
Study: 12823090
Drug: Olanzapine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (2.5 mg/day, titrated to max 10 mg/day)
Study: 12823090
Drug: Risperidone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (0.5 mg/day, titrated to max 2.0 mg/day)
Study: 10863887
Drug: Citalopram (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (40 mg per day)
Study: 9001899
Drug: M.w vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: M.w vaccine (1 x 10(9) bacilli)
Study: 9001899
Drug: M.w vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: M.w vaccine (5 x 10(9) bacilli)
Study: 29253140
Drug: 120 g
Normalized name: soap 120 gram TOPICAL BAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 g of retraction force
Study: 29253140
Drug: 180 g
Normalized name: GLYCERIN 9 mg in 180 g / PANTHENOL 7 mg in 180 g CUTANEOUS FILM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 g of retraction force
Study: 19597072
Drug: Modified directly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified directly observed therapy (mDOT) for 24 weeks
Study: 19597072
Drug: Modified directly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified directly observed therapy (mDOT) for 48 weeks
Study: 11387501
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups combined (after adjustment for case mix)
Study: 7774451
Drug: Heparin solution
Normalized name: heparin Injectable Solution
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin solution (25U/ml) irrigated during operation
Study: 7774451
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no heparin solution)
Study: 3245859
Drug: 0.1% desonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% desonide cream
Study: 1778534
Drug: 0.05% halometasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% halometasone cream
Study: 3245859
Drug: 0.05% clobetasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% clobetasone 17‐butyrate cream
Study: 29199540
Drug: Acetated Ringer's
Normalized name: ACETATED RINGER'S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetated Ringer's solution (CT group)
Study: 10821345
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II antagonists (AIIA) monotherapy
Study: 10821345
Drug: AIIA dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIIA dose titration
Study: 10821345
Drug: AIIA combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIIA combined with low-dose hydrochlorothiazide (HCTZ)
Study: 10821345
Drug: Other antihypertensive
Normalized name: Other antihypertensives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antihypertensive classes
Study: 8629606
Drug: Serum cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum cholesterol (10 mg/dl higher)
Study: 1452929
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 mg) plus aspirin (350 mg)
Study: 1452929
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 mg) with placebo
Study: 1452929
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 mg) without aspirin
Study: 3969190
Drug: Heparin (2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (2,000 units) added to the second cycle
Study: 31349796
Drug: Supported Protocolized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supported Protocolized Discontinuation (SPD) and Mindfulness-Based Cognitive Therapy (MBCT)
Study: 29603842
Drug: IVIg 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIg 1.0 g/kg
Study: 29603842
Drug: IVIg 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIg 0.5 g/kg
Study: 29603842
Drug: IVIg 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIg 2.0 g/kg
Study: 1731030
Drug: Acellular diphtheria-tetanus-pertussis
Normalized name: DIPHTHERIA/TETANUS/PERTUSSIS VACCINE INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular diphtheria-tetanus-pertussis vaccine and Haemophilus influenzae type b conjugate vaccine given at separate injection sites
Study: 1731030
Drug: Acellular diphtheria-tetanus-pertussis
Normalized name: DIPHTHERIA/TETANUS/PERTUSSIS VACCINE INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular diphtheria-tetanus-pertussis vaccine and Haemophilus influenzae type b conjugate vaccine given at a single site
Study: 3882356
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of preoperatively applied ceftriaxon intravenously at the beginning of anesthesia
Study: 3882356
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic at all (control group)
Study: 31899170
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose behavioral coaching (16 sessions over 24 months)
Study: 31899170
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose behavioral coaching (32 sessions over 24 months)
Study: 31899170
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose behavioral coaching (48 sessions over 24 months)
Study: 25448092
Drug: AS03‐adjuvanted A/turkey/Turkey/1/05
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03‐adjuvanted A/turkey/Turkey/1/05 H5N1 vaccine (3.75 or 7.5 μg HA)
Study: 25448092
Drug: AS03A‐adjuvanted booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03A‐adjuvanted booster vaccine (3.75 μg HA)
Study: 23271615
Drug: Whole apples
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole apples (550 g/day)
Study: 23271615
Drug: Apple pomace
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apple pomace (22 g/day)
Study: 23271615
Drug: Cloudy apple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cloudy apple juice (500 ml/day)
Study: 23271615
Drug: Clear apple
Normalized name: Ensure Clear Apple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clear apple juice (500 ml/day)
Study: 9357934
Drug: 120-min infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 120-min infusion of 10 cal/oz formula
Study: 9357934
Drug: 120-min infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 120-min infusion of 20 cal/oz formula